维普期刊资源整合服务平台（V6.5）

81篇 您的检索式：作者名="Mahon FX"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Analysis of total phosphotyrosine levels in CD34 + cells from CML patients to predict the response to imatinib mesylate treatment 显示文摘	Schultheis B Szydlo R Mahon FX	2005	Blood2005，105，12：	1
2	Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs显示文摘	Tipping AJ Mahon FX Zafirides G	2002	Leukemia2002，16，12：	1
3	Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance显示文摘	Mahon FX Deininger MW Schultheis B	2000	Blood2000，96，3：	1
4	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecularremission for at least 2 years:the prospective, muhicentre Stop Imatinib (STIM) triM显示文摘	Mahon FX R6a D Guilhot J	2010	Lancet Oncol2010，11，：	1
5	Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib 显示文摘	Marin D Bazeos A Mahon FX	2010	J Clin Oncol2010，28，14：	1
6	Hypoxia modifies prolif- eration and differentiation of CD34+ CML cells 显示文摘	Desplat V Faucher JL Mahon FX	2002	Stem Ceils2002，20，4：	1
7	Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:diverse mechanisms of resistance显示文摘	Mahon FX Deininger MW Schultheis B	2000	Blood2000，96，3：	1
8	Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression 显示文摘	Mahon FX Hayette S Lagarde V	2008	Cancer Res2008，68，23：	1
9	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years:the prospective,multicentre Stop Imatinib (STIM) trial显示文摘	Mahon FX Réa D Guilhot J		0，，11：	1
10	Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib 显示文摘	Marin D Bazeos A Mahon FX	2010	J Clin Oncol2010，28，14：	1
11	显示文摘	Hoover RR Mahon FX Melo JV	2002	Blood2002，100，：	1
12	Adherence is the criticalfactor for achieving molecular responses in patients with chronicmyeloid leukemia who achieve complete cytogenetic responses onimatinib 显示文摘	Marin D Bazeos A Mahon FX	2010	JClin Oncol2010，28，14：	1
13	Selection and characterization of BCR-ABL positve cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:diverse mechanisms of resistance显示文摘	Mahon FX Deininger MW Schultheis B	2000	Blood2000，96，3：	1
14	Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571:diverse mechanisms of resistance 显示文摘	Mahon FX Deininger MW Schultheis B	2000	Blood2000，96，：	1
15	MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models显示文摘	Mahon FX Belloc F Lagarde V	2003	Blood2003，101，6：	1
16	Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetie responses on imatinib 显示文摘	Matin D Bazeos A Mahon FX	2010	J Clin Oncol2010，28，14：	1
17	Proteasome inhi- bition specifically sensitizes leukemic cells 1o anthracyclin-in- dueed apoptosis through the accumulation of Bim and Bax pro apoptotic proteins显示文摘	Pigneux A Mahon FX Moreau C audry F	2007	Cancer Biol Ther2007，6，4：	1
18	Restoration of sensitivity to STI 571 in STI 571 resistant chronic myeloid leukemia cells显示文摘	Mahon FX Lagarde V	2001	Blood2001，98，13：	1
19	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained com- plete molecular remission for at least 2 ydars: the prospective, mu- hicentre Stop Imatinib(STIM) trial显示文摘	Mahon FX Rra D Guilhot J	2010	Lancet Oncol2010，11，11：	1
20	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years:The prospective,multicentre Stop Imatinib (STIM)trial显示文摘	Mahon FX Rea D Guilhot J	2010	Lancet Oncol2010，11，11：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示